These results were similar to those reported by Hsu I-Ling et al. [24] who found that, compared with ovarian cancer cells expressing low levels of FXYD2, those with high expression were more sensitive to cardiosides, while cardiotonic glycosides can effectively inhibit the growth of ovarian cancer cells. Here, FXYD2 is linked to ovarian carcinoma.